Skip to main content

Skip to main content

Overview

SEC Filings Details

Overview

Form 4

01/26/2026

Statement of Changes in Beneficial Ownership

PDF Format Download (opens in new window)
Excel Format Download (opens in new window)

We are a clinical-stage biotechnology company focused on developing proprietary new therapies to enhance the function of regulatory T cells. We are currently developing our multi-modality Treg therapies for neurodegenerative, autoimmune, and metabolic diseases.

Links

SEC Filings
Information Request Form

IR Contact

David Snyder

IR@coyatherapeutics.com

Email Alerts

To opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. After submitting your request, you will receive an activation email to the requested email address. You must click the activation link in order to complete your subscription. You can sign up for additional alert options at any time.

At Coya Therapeutics, we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance.

By providing your email address below, you are providing consent to Coya Therapeutics to send you the requested Investor Email Alert updates.

* Required

Email Address *

Investor Alert Options

Investor Alert Options *

News

Events & Presentations

Quarterly Reports

Annual Reports

SEC Filings

Unsubscribe

Email Alert Sign Up Confirmation

Terms of Use
Privacy Policy

© Coya Therapeutics, Inc. All rights reserved

Powered By Q4 Inc. 5.177.0.3 (opens in new window)